NYU Langone


 

2020 CheckMate 238 Update on IO in Advanced Stage Melanoma: Did Nivo Show Sustained Superior Patient Benefit vs. Ipi in High-Risk Resected Disease?

1,145 views
November 9, 2020
Comments 1
Login to view comments. Click here to Login